Clinical Trials Logo

Bioequivalence clinical trials

View clinical trials related to Bioequivalence.

Filter by:

NCT ID: NCT06331715 Not yet recruiting - Bioequivalence Clinical Trials

Bioequivalence Study of Palbociclib 125 mg Capsules of Iclos vs. Ibrance (Palbociclib) Capsules 125 mg

Start date: May 6, 2024
Phase: Phase 4
Study type: Interventional

An open label, balanced, randomized, two treatments, two sequences, two periods, cross over, single dose, bioequivalence study of Palbociclib 125 mg Capsules of Iclos Uruguay S.A and IBRANCE® (Palbociclib) 125 mg Capsules of Pfizer Europe (Belgium) in healthy, adult, human subjects under fed condition.

NCT ID: NCT06213610 Recruiting - Bioequivalence Clinical Trials

Bioequivalence Study of Perindopril Tablets in Healthy Volunteers Under Fasting Conditions

Start date: January 9, 2024
Phase: Phase 1
Study type: Interventional

This is an open-labeled, randomized, two period, single-center, crossover, comparative study, where each participant will be randomly assigned to the reference (Prestarium ® A 10 mg tablets) or the test (Perindopril 8 mg tablets) formulation in each period of study (sequences Test-Reference (TR) or Reference-Test (RT)), in order to evaluate if both formulations are bioequivalent.

NCT ID: NCT06164431 Completed - Bioequivalence Clinical Trials

Bioavailability Study in Healthy Participants, 200mg Tablets ZSP1273 Versus 200mg Granules ZSP1273

Start date: November 23, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to establish bioavailability of 2 treatments with ZSP1273: 200mg tablets and 200mg granules will be given to healthy Participants under fasting conditions. Bioavailability will be evaluated and verified on the basis of pharmacokinetic data.

NCT ID: NCT06124573 Completed - Clinical trials for Diabetes Mellitus, Type 2

Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 100 mg /1000 mg (FDC) in Healthy Adult Male and Female Subjects Under Fed Conditions.

Start date: November 7, 2022
Phase: Phase 1
Study type: Interventional

The objective of this study was to evaluate and compare the bioavailability and therefore to assess the bioequivalence of two different formulations of sitagliptin/metformin extended release tablets after a single oral dose administration under fed conditions.

NCT ID: NCT06124560 Completed - Clinical trials for Diabetes Mellitus, Type 2

Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 100 mg /1000 mg (FDC) in Healthy Adult Male and Female Subjects Under Fasting Conditions.

Start date: October 28, 2022
Phase: Phase 1
Study type: Interventional

The objective of this study was to evaluate and compare the bioavailability and therefore to assess the bioequivalence of two different formulations of sitagliptin/metformin extended release tablets after a single oral dose administration under fasting conditions.

NCT ID: NCT06124547 Completed - Clinical trials for Diabetes Mellitus, Type 2

Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 50 mg /500 mg (FDC) in Healthy Adult Male and Female Subjects Under Fed Conditions.

Start date: January 16, 2023
Phase: Phase 1
Study type: Interventional

The objective of this study was to evaluate and compare the bioavailability and therefore to assess the bioequivalence of two different formulations of sitagliptin/metformin extended release tablets after a single oral dose administration under fed conditions.

NCT ID: NCT06124495 Completed - Clinical trials for Diabetes Mellitus, Type 2

Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 50 mg /500 mg (FDC) in Healthy Adult Male and Female Subjects Under Fasting Conditions.

Start date: January 13, 2023
Phase: Phase 1
Study type: Interventional

The objective of this study was to evaluate and compare the bioavailability and therefore to assess the bioequivalence of two different formulations of sitagliptin/metformin extended release tablets after a single oral dose administration under fasting conditions.

NCT ID: NCT06066112 Recruiting - Schizophrenia Clinical Trials

Study on the Bioequivalence of Amisulpride Orally Disintegrating Tablets in Human Body

Start date: September 20, 2023
Phase: Phase 1
Study type: Interventional

The experiment adopts a single center, randomized, open, single dose, two cycle, and double crossover design. The subjects were randomly divided into TR and RT groups. In the first cycle, they received the test or control formulation on an empty stomach or after a meal. After a cleaning period, they entered the second cycle and received the control or test formulation in the same state. The cleaning period between the two cycles was 7 days.

NCT ID: NCT06050343 Completed - Bioequivalence Clinical Trials

Comparative Study of Rinsulin R (GEROPHARM) and Humulin Regular (Eli Lilly) Euglycemic Hyperinsulinemic Clamp Method

Start date: February 19, 2018
Phase: N/A
Study type: Interventional

Pharmacokinetics and pharmacodynamics of Rinsulin® R, injection solution, 100 IU / ml (GEROPHARM LLC, Russia) and Humulin® Regular, injection solution, 100 IU / ml (Lilly France ", France) using the euglycemic hyperinsulinemic clamp method.

NCT ID: NCT06025214 Recruiting - Bioequivalence Clinical Trials

Bioequivalence Study for Fluticasone Propionate 500 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers

Start date: August 22, 2023
Phase: Phase 1
Study type: Interventional

Bioequivalence study between two inhaler products of fixed dose combination of fluticasone propionate and salmeterol xinafoate inhalation powder